A new generation of human model systems are coming to the forefront of drug development, including novel organoid, microphysiological and in silico platforms. With the passage of the FDA Modernization Act 2.0 in 2022, these cutting-edge systems are poised to gain increasing scientific, commercial and regulatory acceptance in replacing data traditionally sought from animal models. But how far can these systems go in displacing animals, and what commercial and regulatory challenges stand in their path?
Join us as we convene a panel of experts in alternative human model systems to discuss their changing role in science and business.
Panelists:
• Lowry Curley, Ph.D., Co-Founder and CEO of Axosim
• Krista Durney, Ph.D., Associate Director, Innovation & Business Development at Valo Health
• Kristin Bircsak, Ph.D., Principal Scientist at MIMETAS
• Iris Bica, Business Development & Licensing Associate at Weill Cornell Medicine (Moderator)